Amylyx Pharmaceuticals, Inc. (AMLX)Healthcare | Drug Manufacturers - Specialty & Generic | Cambridge, United States | NasdaqGS
18.36 USD
+0.63
(3.553%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 18.40 +0.04 (0.218%) ⇧ (April 17, 2026, 7:54 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:12 a.m. EDT
Cautious BLS bulls with a defensive underlay. The stock shows strong technical momentum (recent 14-day rally over 40%) and insider support, yet the forecast model predicts a -2.3% drop over the next 45 days, likely citing ongoing burn rate and clinical trial risks. The heavy put positioning at $12 levels acts as insurance against volatility rather than a bearish bet. Unless Lucidity trial results accelerate approval or revenue generation is confirmed, the high negative P/E and negative EPS prevent a strong bullish rating, limiting this to a 'slight upside lean' play suitable for momentum traders with an eye on the hedge-heavy support at lower price levels. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.082364 |
| AutoETS | 0.082552 |
| AutoARIMA | 0.082554 |
| MSTL | 0.096616 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 66% |
| H-stat | 1.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.047 |
| Excess Kurtosis | 0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.951 |
| Market Cap | 2,029,458,304 |
| Forward P/E | -14.99 |
| Beta | -0.21 |
| Website | https://amylyx.com |
As of April 19, 2026, 12:12 a.m. EDT: The options chain reveals a distinct bullish sentiment concentrated in lower strikes (ITM or ATM) with significant Open Interest at the $15 and $17 strikes across multiple expirations. Notably, for the $17.00 June 2026 expiration, there is a 'New Flow' signal where volume (30) exceeds open interest (11), indicating fresh buying pressure at current levels. However, the market is also heavily hedged against downside risk, evidenced by massive ($760k) OTM Put Open Interest at the $12 and $13 strikes for the April 17 expiration (prior to the April 17 earnings context). This heavy put OI at levels significantly below the current price creates a 'floor' effect, suggesting speculators expect volatility or a dip but are not betting aggressively on a crash. The call skew is slightly more active in volume than puts for near-term, but the heavy put OI suggests a strategy of paying to be on the short side or hedging long positions.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.3404255 |
| Address1 | 55 Cambridge Parkway |
| Address2 | Suite 6W |
| All Time High | 41.93 |
| All Time Low | 1.575 |
| Ask | 23.0 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,415,660 |
| Average Daily Volume3 Month | 1,209,569 |
| Average Volume | 1,209,569 |
| Average Volume10Days | 1,415,660 |
| Beta | -0.213 |
| Bid | 13.28 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.778 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.36 |
| Current Ratio | 14.266 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 18.605 |
| Day Low | 17.75 |
| Debt To Equity | 1.951 |
| Display Name | Amylyx Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,542,800 |
| Earnings Call Timestamp Start | 1,772,542,800 |
| Earnings Timestamp | 1,772,544,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -152,766,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.249 |
| Enterprise Value | 1,718,436,352 |
| Eps Current Year | -1.305 |
| Eps Forward | -1.22518 |
| Eps Trailing Twelve Months | -1.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.738 |
| Fifty Day Average Change | 3.6220007 |
| Fifty Day Average Change Percent | 0.24575931 |
| Fifty Two Week Change Percent | 334.04254 |
| Fifty Two Week High | 18.605 |
| Fifty Two Week High Change | -0.24499893 |
| Fifty Two Week High Change Percent | -0.013168446 |
| Fifty Two Week Low | 3.94 |
| Fifty Two Week Low Change | 14.42 |
| Fifty Two Week Low Change Percent | 3.6598985 |
| Fifty Two Week Range | 3.94 - 18.605 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,641,565,800,000 |
| Float Shares | 82,882,811 |
| Forward Eps | -1.22518 |
| Forward P E | -14.985554 |
| Free Cashflow | -66,994,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 136 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -90,404,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07948 |
| Held Percent Institutions | 1.0443801 |
| Implied Shares Outstanding | 110,536,944 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,022-01-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Amylyx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,029,458,304 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_317169670 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -144,735,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,029,458,291 |
| Number Of Analyst Opinions | 10 |
| Open | 18.2 |
| Operating Cashflow | -123,343,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 682 0917 |
| Post Market Change | 0.03999901 |
| Post Market Change Percent | 0.21785952 |
| Post Market Price | 18.4 |
| Post Market Time | 1,776,470,085 |
| Previous Close | 17.73 |
| Price Eps Current Year | -14.068967 |
| Price Hint | 2 |
| Price To Book | 6.6090713 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.98 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.630001 |
| Regular Market Change Percent | 3.55331 |
| Regular Market Day High | 18.605 |
| Regular Market Day Low | 17.75 |
| Regular Market Day Range | 17.75 - 18.605 |
| Regular Market Open | 18.2 |
| Regular Market Previous Close | 17.73 |
| Regular Market Price | 18.36 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,519,415 |
| Return On Assets | -0.36409 |
| Return On Equity | -0.61586 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 110,536,944 |
| Shares Percent Shares Out | 0.1287 |
| Shares Short | 14,231,261 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,497,298 |
| Short Name | Amylyx Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1392 |
| Short Ratio | 13.56 |
| Source Interval | 15 |
| State | MA |
| Symbol | AMLX |
| Target High Price | 34.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 22.8 |
| Target Median Price | 20.5 |
| Total Cash | 316,979,008 |
| Total Cash Per Share | 2.868 |
| Total Debt | 5,957,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.6095 |
| Two Hundred Day Average Change | 5.7505007 |
| Two Hundred Day Average Change Percent | 0.4560451 |
| Type Disp | Equity |
| Volume | 1,519,415 |
| Website | https://amylyx.com |
| Zip | 2,142 |